Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice

Journal of Neuroscience

Volumn 26, Issue 20, 2006, Pages 5340-5346

  Wilcock, Donna M ^a   Alamed, Jennifer ^a   Gottschall, Paul E ^a   Grimm, Jan ^b   Rosenthal, Arnon ^b   Pons, Jaume ^b   Ronan, Victoria ^a   Symmonds, Keisha ^a   Gordon, Marcia N ^a   Morgan, Dave ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Rinat Neuroscience   (United States)

Author keywords

Alzheimer's; CAA; Immunotherapy; Microglia; Microhemorrhage; Vaccination

Indexed keywords

AMYLOID BETA ANTIBODY; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CONGO RED; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG ACTIVITY; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAZE TEST; MOUSE; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS; AGING; ALZHEIMER DISEASE; ANIMAL; BLOOD VESSEL; BRAIN; CEREBRAL ARTERY DISEASE; DISEASE MODEL; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; GLYCOSYLATION; IMMUNOTHERAPY; MEMORY DISORDER; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SENILE PLAQUE; TRANSGENIC MOUSE; TREATMENT OUTCOME;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; BLOOD VESSELS; BRAIN; CEREBRAL ARTERIAL DISEASES; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GLYCOSYLATION; IMMUNOTHERAPY; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; SENILE PLAQUES; TREATMENT OUTCOME;

EID: 33745001453     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0695-06.2006     Document Type: Article

References (28)

1. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci 22:7873-7878.
2. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 6:916-919.
3. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, et al. (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100:2023-2028.
4. Carty NC, Wilcock DM, Rosenthal A, Grimm J, Ronan V, Gottschall PE, Gordon MN, Morgan D (2006) Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid depositing transgenic mice. J Neuroinflammation, in press.
5. -/- knock-out mice. J Neurosci 23:8532-8538.
6. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzehimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
7. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, De-Long CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5:452-457.
8. Ferrer I, Boada R, Sanchez M, Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14:11-20.
9. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KW, Hope CE, Hatcher JM, DiCarlo G, Gottschall PE, Morgan D, Arendash GW (2001) Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging 22:377-385.
10. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
11. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
12. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
13. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22:6331-6335.
14. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129-131.
15. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
16. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448-452.
17. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46-54.
18. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2001) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379.
19. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J Neurosci 25:629-636.
20. Radaev S, Sun PD (2001) Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem 276:16478-16483.
21. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
22. Solomon B, Koppel R, Frenkel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed monoclonal antibodies. Proc Natl Acad Sci USA 94:4109-4112.
23. Walker MR, Lund J, Thompson KM, Jefferis R (1989) Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 259:347-353.
24. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D (2003) Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms independent of and associated with microglial activation. J Neurosci 213:3745-3751.
25. Wilcock DM, Muniredddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D (2004a) Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration. Neurobiol Dis 15:11-20.
26. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D (2004b) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24:6144-6151.
27. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004c) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1:24.
28. Winkelhake, JL Kunicki, TJ Elcombe, BM Aster RH (1980) Effects of pH treatments and deglycosylation of rabbit immunoglobulin G on the binding of C1q. J Biol Chem 255:2822-2828.